A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Last updated: March 5, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Terminated

Phase

1

Condition

Small Cell Lung Cancer

Treatment

JDQ443

Clinical Study ID

NCT05329623
CJDQ443B12103
  • Ages 18-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.

Eligibility Criteria

Inclusion

Key inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.

  • Participants must weigh at least 50.0 kg to participate in the study and must have abody mass index (BMI) within the range of 18 to 40 kg/m2.

  • Ability to communicate well with the investigator, to understand and comply with therequirements of the study.

  • Participant must be willing to remain in the clinical research unit as required bythe protocol.

Exclusion

Key exclusion Criteria:

  • Use of other investigational drugs within the last 30 days or 5 half-lives prior todosing, whichever is longer.

  • Use of drugs (prescription, non-prescription and herbal remedies such as St John'swort) known to affect cytochrome p (CYP)3A, including both strong and moderateinhibitors and inducers, within 2 weeks prior to dosing until completion of the EOSVisit.

  • Contradiction or hypersensitivity to the investigational compound/compound class orits excipients being used in this study.

  • Pregnant or nursing (lactating) women. Pregnancy is defined as the state of a femaleafter conception and until termination of gestation, confirmed by a positive humanchorionic gonadotropin (hCG) laboratory test.

  • Known history of, or current clinically significant arrhythmias, history ofprolonged QT correction formula (QTcF) interval or QTcF >480 msec

Other inclusion/exclusion criteria may apply

Study Design

Total Participants: 33
Treatment Group(s): 1
Primary Treatment: JDQ443
Phase: 1
Study Start date:
May 03, 2022
Estimated Completion Date:
April 07, 2024

Study Description

This is a Phase 1, open-label, single-dose, multi-center, parallel group study to evaluate the PK of oral JDQ443 in participants with mild, moderate, and/or severe hepatic impairment compared to matched healthy control participants.

The study comprises a 28-day Screening period (Days -28 to -2), a baseline evaluation period (Day -1), a single dose administration of 200 mg of JDQ443 (Day 1), and a follow-up period of 4 days (Days 2 to 4) for PK sample collection. All participants should have a post-study safety follow-up contact conducted approximately 30 days after last administration of study treatment. The study will be considered complete once all the participants have finished the required assessments or have dropped out or been lost to follow-up.

A total of up to 48 participants will be enrolled in this study. Approximately 8 participants will be enrolled in each of mild (Child-Pugh A; Group 2), moderate (Child-Pugh B; Group 3), and severe (Child-Pugh C; Group 4) hepatic impairment groups (to have at least six evaluable participants in each group). Each participant in the healthy control group (Group 1) will be matched to one or more evaluable participants with hepatic impairment with respect to age, body weight and sex. All participants will receive a single JDQ443 dose. Upon completion of mild and moderate impairment groups, as well as matching control participants, an interim analysis will be conducted to compare the PK exposure of the two hepatic impaired groups (Groups 2 and 3) to that of the control participants. The interim analysis is to mitigate the potential safety risks in participants with severe hepatic impairment. If the interim analysis results do not show a clinically relevant increase in exposure of JDQ443 and is well tolerated from a safety perspective, then severe hepatic impairment participants may be enrolled. Participants with severe hepatic impairment will be enrolled only after the completion of the interim analysis.

Connect with a study center

  • Orlando Clinical Research Center

    Orlando, Florida 32809
    United States

    Site Not Available

  • Texas Liver Institute

    San Antonio, Texas 78215
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.